To the Editor:
In a phase I clinical trial of venetoclax in patients with t (11;14) relapsed/refractory multiple myeloma (MM), 40% of the patients treated achieved an objective response [1] . While this response rate with a single agent in MM is impressive, it demonstrates that t(11;14) is not an optimal biomarker for response to venetoclax. Functional profiling of BCL2 family members has been shown to predict responses to therapy in myeloma and other diseases [2] . Therefore, we set out to determine how ex vivo sensitivity to venetoclax corresponds to clinical response and resistance.
We performed ex vivo apoptosis assays on a cohort of 76 samples collected from 65 patients (Supplemental Table 1 (11;14) was the only significant difference between the sensitive group and the others (Supplemental Table 2 ). Twenty patients received venetoclax as a single agent (n = 10) or in combination with dexamethasone (n = 9) or daratumamab/dexamethasone (n = 1) and 18 had ex vivo sensitivity tested immediately prior to venetoclax treatment (Supplemental Tables 1 and 3) . A patient with nonsecretory disease and another that withdrew consent prior to completing one cycle were not included in this analysis. Ten of the 16 remaining patients had a clinical response (partial response (PR) or better), nine of which were in the most sensitive cohort. Only one of the six nonresponding patients was in the most sensitive group (Fig. 1c) . Thus, the sensitivity of the assay is 0.9 while the specificity is 0.83 (Fisher's exact test, P = 0.0076). Examples of ex vivo concentration−response curves and clinical responses are provided in Supplemental Figure 1 . Together these data suggest that ex vivo pretreatment sensitivity can predict patient responses to venetoclax.
Of the patients who responded to venetoclax, three had both a pretreatment and postrelapse sample that was analyzed (Fig. 1d) . MM93 had an initial IC 50 of 8 nM and achieved a PR for 8 months (Supplemental Figure 2) . In the posttreatment sample the IC 50 increased to 70 nM (Fig. 1d , left panel). While this would still be considered a sensitive sample in the ex vivo analysis, it does represent a nearly ninefold increase in IC 50 posttreatment. MM100 had nonsecretory disease; however, while on venetoclax the patient demonstrated a hematologic recovery. This "response" was transient and the patient became cytopenic after 3 months (Supplemental Figure 2) . Consistent with the development of venetoclax resistance, ex vivo testing indicated that the IC 50 had increased from 4 to 1870 nM (Fig. 1d) . MM91 had an initial IC 50 of 20 nM when the combination of daratumumab, venetoclax, and dexamethasone was initiated. The patient had a very good partial response that lasted for over 11 months before progression. The posttreatment IC 50 increased over 400-fold to 8100 nM (Fig. 1d) . Finally, for two patients who were treated, no pretreatment sample was available; however, a postrelapse sample was tested for ex vivo sensitivity. In both cases the sample tested as moderately or highly resistant to venetoclax (Fig. 1d, right  panel) . MM77 achieved a stringent complete response that was maintained for 15 months. The postrelapse sample was highly resistant to ex vivo venetoclax treatment (IC 50 , 12,000 nM). MM99 had stable disease for nearly 6 months before treatment was stopped. The posttreatment sample displayed sensitivity consistent with our pretreatment nonresponder population (IC 50 , 200 nM). Thus, posttreatment ex vivo testing reflects development of venetoclax resistance.
In addition to testing serial samples from patients who were treated with venetoclax, we were able to test samples from six patients who were not treated with venetoclax to determine if clonal changes associated with other therapy could influence ex vivo sensitivity. We observed a decrease in ex vivo IC 50 with two patients, an increase in ex vivo IC 50 in three patients and one patient who had no change ( Supplementary Figures 3 and 4) .
We previously demonstrated that dexamethasone could synergize with venetoclax by increasing the expression of the proapoptotic BH3-only protein BIM and subsequent priming of BCL2 [4] . This combination resulted in an increase in the response rate of t(11;14)-positive patients from 40% in the initial study to 65% [5] . We analyzed the ven/dex combination in 46 samples, including our original cohort of 9. Only 11 samples demonstrated ex vivo sensitivity to dexamethasone alone as defined by induction of at least 25% cell death. Therefore, the majority of responses observed are due to sensitization while in the 11 that showed dexamethasone sensitivity we cannot rule out additive or synergistic effects if the cells were also sensitive to venetoclax. The decrease in IC50 with dexamethasone was significant in all three sensitivity cohorts. In the Fig. 1 Ex vivo response of patient-derived plasma cells to venetoclax. Buffy coat cells were treated with venetoclax for 24 h and apoptosis of the plasma cells was determined as described in the Supplemental Methods section. Dose curves using concentrations of 0, 10, 100, and 1000 nM venetoclax were used to calculate the IC 50 for each patient sample. a The samples were clustered based on the presence (n = 31) or absence (n = 36) of the t(11;14) translocation and graphed according to IC 50 . Whiskers extend from 10 to 90%, P = 0.0176. Postvenetoclax treatment samples were removed from this analysis due to the effects of acquired resistance. b Samples separated into three categories according to venetoclax sensitivity; Green-highly sensitive, IC 50 most sensitive cohort, the median IC 50 decreased from 40 to 9.5 nM with dexamethasone (P ≤ 0.0001). However, 5/20 samples were sensitive to dexamethasone alone suggesting that this change could be in part due to an additive response to two active drugs (Fig. 2a) . Dexamethasone had a more profound effect on the intermediate population where 7/10 samples had an IC50 shift to the most sensitive cohort (Fig. 2b, median IC 50 325 vs. 60 nM with dexamethasone, P = 0.0020). While 5/10 samples were sensitive to dexamethasone alone, they are not considered sensitive to venetoclax alone; so this is unlikely to be an additive response, more likely reflecting synergy or sensitization. Similar results were observed in the most resistant population where 8/15 samples shifted to an IC 50 consistent with a more sensitive cohort (median IC 50 3250 vs. 810 nM for the combination, P ≤ 0.0001). Only one of these samples was sensitive to dexamethasone alone. Amazingly three of these samples were now in the most sensitive cohort demonstrating a >1 log shift in the venetoclax IC 50 (Fig. 2c) . Of the ten samples that were sensitized by dexamethasone to an IC 50 consistent with the sensitive cohort, only half were t (11;14) suggesting this may be an effective way to increase the response rate of venetoclax in both t(11;14)-positive and -negative myeloma.
Together our data represent an alternative approach to precision medicine that utilizes functional testing rather than Fig. 1b targeting of acquired mutations or structural variations [6, 7] . The latter have had limited success due to the heterogeneity of these events within a tumor or availability of targeted therapy [8, 9] . Targeting tumor dependence on BCL2 for survival, which is typically not based on mutations or translocations, is a promising new approach and has been used effectively in CLL [10, 11] . Our results build on the preclinical BH3 profiling and ex vivo testing with venetoclax first used to demonstrate BCL2 dependence in t (11;14) myeloma [3, 12, 13] . We applied functional profiling of BCL2 dependence to a large series of myeloma patient samples and consistent with previous findings demonstrated that t(11;14) was the only commonly tested marker that was associated with ex vivo venetoclax sensitivity [3] . However consistent with previous studies of cell lines, patients samples, and the phase I venetoclax monotherapy trial, t(11;14) samples can be resistant to venetoclax and non-t(11;14) samples can be sensitive [1] . Therefore, we focused on the functional responses of the samples as opposed to genomic alterations to define BCL2 dependence. Since these cohorts included patients treated with venetoclax (both pre-and post-treatment) we were able to determine what level of ex vivo drug sensitivity associated with clinical response. There was a strong correlation with ex vivo sensitivity as 90% of the responding patients fell in the most sensitive cohort and 83% of the nonresponding patients were in the other two cohorts. This compares favorably to the use of expression ratios, which worked best when the ratio was high [1] . Moreover, all posttreatment samples showed a significant increase in their IC 50 . While the total number of treated patients evaluated in this study is small, it is the first example of a patient cohort where clinical and ex vivo responses were both measured.
Our findings also demonstrate the dynamic nature of BCL2 dependence and the importance of when sensitivity is tested relative to initiation of treatment. We observed significant changes in sensitivity of samples taken from patients at different points of treatment. This could reflect clonal heterogeneity of myeloma and the effects of previous treatments on the makeup of the disease at any given time [14, 15] . Alternatively, it could be due to changes in mitochondrial priming associated with therapy [16] .
Finally, ex vivo testing demonstrates the ability of dexamethasone to convert some venetoclax-insensitive or even -resistant cells to clinically sensitive samples. This combination has already been shown to have significant activity in t(11;14) patients compared to single-agent venetoclax [5] . Our data point to the possibility of using this combination in a broader spectrum of myeloma patients beyond the 15−20% that are t(11;14)-positive.
